Background: Hemodialysis vascular access failure occurs often and increases morbidity for people on hemodialysis therapy. Antiplatelet agents may prevent hemodialysis vascular access failure, but potentially may be hazardous in people with end-stage kidney disease who have impaired hemostasis.Study Design: Systematic review and meta-analysis of randomized controlled trials.Setting & Population: Adults on long-term hemodialysis therapy.Selection Criteria: Trials evaluating hemodialysis vascular access outcomes identified by searches in Cochrane CENTRAL and Renal Group Trial Registers and Embase, without language restriction.Intervention: Antiplatelet therapy.Outcomes: Hemodialysis vascular access failure (thrombosis or loss of patency), ...
Background. Renal failure is a major cause of morbidity in western Europe, with rising prevalence. V...
Background: Arteriovenous fistula (AVF) is the primary mode of achieving vascular access for hemodia...
Background. Vascular access failure is the most common cause of morbidity and hospitalization in hae...
Background: Hemodialysis vascular access failure occurs often and increases morbidity for people on ...
BACKGROUND:In this study, we evaluated the effects of various medications on the patency of vascular...
BackgroundIn this study, we evaluated the effects of various medications on the patency of vascular ...
Objective: Dialysis access failure is a major cause of morbidity, mortality, and cost in end-stage r...
Background: Arteriovenous fistula (FAV) is the most widely used vascular access for end-stage renal ...
CONTEXT: The arteriovenous fistula is the preferred type of vascular access for hemodialysis because...
ObjectiveDialysis access failure is a major cause of morbidity, mortality, and cost in end-stage ren...
<p>Background. Renal failure is a major cause of morbidity in western Europe, with rising prevalence...
Renal failure is a major cause of morbidity in western Europe, with rising prevalence. Vascular acce...
Background: Antiplatelet agents are used to prevent cardiovascular events; however, treatment effect...
Background: Antiplatelet agents are widely used to prevent cardiovascular events. The risks and bene...
International audiencePURPOSE:Results of previous studies assessing the risk of bleeding associated ...
Background. Renal failure is a major cause of morbidity in western Europe, with rising prevalence. V...
Background: Arteriovenous fistula (AVF) is the primary mode of achieving vascular access for hemodia...
Background. Vascular access failure is the most common cause of morbidity and hospitalization in hae...
Background: Hemodialysis vascular access failure occurs often and increases morbidity for people on ...
BACKGROUND:In this study, we evaluated the effects of various medications on the patency of vascular...
BackgroundIn this study, we evaluated the effects of various medications on the patency of vascular ...
Objective: Dialysis access failure is a major cause of morbidity, mortality, and cost in end-stage r...
Background: Arteriovenous fistula (FAV) is the most widely used vascular access for end-stage renal ...
CONTEXT: The arteriovenous fistula is the preferred type of vascular access for hemodialysis because...
ObjectiveDialysis access failure is a major cause of morbidity, mortality, and cost in end-stage ren...
<p>Background. Renal failure is a major cause of morbidity in western Europe, with rising prevalence...
Renal failure is a major cause of morbidity in western Europe, with rising prevalence. Vascular acce...
Background: Antiplatelet agents are used to prevent cardiovascular events; however, treatment effect...
Background: Antiplatelet agents are widely used to prevent cardiovascular events. The risks and bene...
International audiencePURPOSE:Results of previous studies assessing the risk of bleeding associated ...
Background. Renal failure is a major cause of morbidity in western Europe, with rising prevalence. V...
Background: Arteriovenous fistula (AVF) is the primary mode of achieving vascular access for hemodia...
Background. Vascular access failure is the most common cause of morbidity and hospitalization in hae...